Can I Take Creatine with Fosamax (Alendronate)?

The Short Answer on Alendronate and Creatine

No head-to-head randomized trial has studied alendronate plus creatine specifically, but the existing pharmacology gives a clear picture. Alendronate is absorbed in the proximal small intestine within 30 to 60 minutes of ingestion, and its oral bioavailability is already poor (roughly 0.6% under ideal conditions). Creatine does not bind to the same transporters, does not alter gastric pH in a clinically meaningful way, and does not affect CYP450 enzymes. The two compounds travel completely separate metabolic paths.

The concern that does deserve attention is the effect of creatine loading on serum creatinine measurements, and the downstream consequences for a drug whose prescribing label explicitly references renal function thresholds.

Why Alendronate Has a Renal Threshold at All

Alendronate is eliminated almost entirely by the kidneys unchanged. The FDA-approved prescribing information states it should not be used in patients with creatinine clearance below 35 mL/min because dose accumulation in bone has not been adequately studied below that threshold [1]. Most healthy adults on standard osteoporosis therapy sit comfortably above that cutoff, but patients with mild chronic kidney disease (CKD stages 1 to 2) may hover near the boundary. Any lab change that nudges an eGFR reading downward could trigger an unnecessary drug hold.

How Creatine Supplements Affect Creatinine Labs

Creatine is converted non-enzymatically to creatinine in muscle tissue, and supplemental creatine increases the substrate pool available for that conversion. A crossover trial published in the Journal of Renal Nutrition (N=18 healthy adults) found that 5 g/day creatine monohydrate for five days raised mean serum creatinine by approximately 0.15 mg/dL, corresponding to a roughly 13% increase, without any true change in glomerular filtration rate measured by inulin clearance [2]. The CKD-EPI and MDRD equations both use serum creatinine as their input, so a creatinine artifact translates directly into an artificially depressed eGFR estimate.

If your prescriber runs a routine metabolic panel while you are mid-creatine-loading phase, the number on the report may look worse than reality. Proactively telling your provider you are taking creatine is the simplest intervention available.

Pharmacokinetics: Do These Two Compounds Interfere With Each Other?

Absorption Timing and Alendronate's Strict Window

Alendronate has one of the strictest dosing protocols of any oral medication. Patients must take it first thing in the morning with 6 to 8 oz of plain water, remain upright for at least 30 minutes, and eat nothing else during that window [1]. This is not a drug-specific quirk. Any divalent cation (calcium, magnesium, iron, zinc) chelates alendronate and reduces its already minimal absorption. Most protein powders and creatine pre-mixes contain added minerals or are dissolved in dairy or fortified beverages.

The practical rule: take alendronate first, wait the full 30 minutes, then take creatine dissolved in plain water or juice if you prefer. This timing gap alone eliminates any theoretical absorption competition.

Protein Binding and Volume of Distribution

Alendronate binds to hydroxyapatite in bone after systemic absorption; it has essentially no plasma protein binding relevant to drug displacement. Creatine distributes into muscle via the sodium-coupled creatine transporter (SLC6A8) and does not compete with any alendronate pathway. No pharmacodynamic antagonism exists either. Alendronate inhibits farnesyl pyrophosphate synthase in osteoclasts. Creatine replenishes phosphocreatine stores in muscle. These mechanisms share zero overlap at the molecular level.

Renal Elimination: Where Caution Is Warranted

Both compounds rely on renal excretion, but they use separate tubular handling. Alendronate undergoes no metabolism and is excreted unchanged [1]. Creatinine (the creatine metabolite) is filtered at the glomerulus with modest tubular secretion. The parallel renal routes do not create a competition for clearance, but both produce signals that clinicians read as indicators of kidney health. Recognizing this shared reliance on renal monitoring is the core of safe co-administration.

Creatine's Effect on Kidney Function: Real Risk vs. Lab Artifact

Separating the Creatinine Signal From True GFR

A 2021 review in Nutrients examined 15 controlled studies of creatine supplementation and renal biomarkers in adults without pre-existing kidney disease [3]. Across those trials, serum creatinine rose in a dose-dependent pattern, peaking during loading phases (typically 20 g/day for 5 to 7 days), then stabilizing at a new slightly elevated plateau on maintenance dosing (3 to 5 g/day). Measured GFR via cystatin C, which is not affected by creatine loading, remained statistically unchanged. The authors concluded that the creatinine elevation is a non-pathological metabolic effect, not evidence of nephrotoxicity.

Cystatin C is an alternative filtration marker the body produces at a constant rate regardless of muscle mass or creatine intake. If your prescriber has access to a cystatin C-based eGFR, it offers a much cleaner read of true kidney function during creatine supplementation.

When Real Renal Risk Could Apply

Patients with pre-existing CKD stages 3 or higher carry a different risk profile. A case series published in Nephrology Dialysis Transplantation described three patients with previously unrecognized mild CKD who developed clinically significant creatinine rises (not purely artifactual) after aggressive creatine loading at 20 g/day [4]. None of these patients were on alendronate, and loading doses that high are not standard maintenance practice, but the report underscores the need for baseline labs before starting creatine in any patient on a renally-cleared drug. Standard maintenance creatine (3 to 5 g/day) has not been associated with true GFR decline in individuals with preserved renal function.

Monitoring Checklist Before You Start Both

Getting a complete metabolic panel (CMP) and eGFR before beginning creatine is the single most protective step for someone already on alendronate. A baseline creatinine of 0.85 mg/dL that rises to 0.99 mg/dL after four weeks on creatine is almost certainly an artifact. Without that baseline number on file, a provider seeing 0.99 mg/dL cold may flag it as abnormal and question whether alendronate should continue.

Potential Benefits: Does Creatine Help With Osteoporosis?

Alendronate is prescribed specifically to preserve or increase bone mineral density (BMD). The question of whether creatine might add a complementary effect is genuinely interesting.

Creatine Plus Resistance Training and Bone

A double-blind randomized controlled trial published in Medicine and Science in Sports and Exercise (N=120, mean age 58 years, post-menopausal women) assigned participants to resistance training plus creatine (0.1 g/kg/day) or placebo [5]. At 52 weeks, the creatine group showed a statistically significant preservation of femoral neck BMD compared to the placebo group (P<0.05). The mechanism is indirect: creatine improves high-intensity exercise capacity, which generates greater mechanical loading on bone, and bone responds to mechanical loading by increasing density via osteoblast activation.

This does not mean creatine replaces alendronate. The effect size for bisphosphonates on BMD far exceeds what creatine and resistance training alone produce. The 2020 American College of Rheumatology guideline for glucocorticoid-induced osteoporosis names oral bisphosphonates as first-line pharmacotherapy without mention of any supplement as an equivalent substitute [6]. Creatine, when used alongside resistance training, may produce additive mechanical-loading benefits on top of the cellular osteoclast suppression that alendronate provides.

Does Alendronate's Mechanism Interact With Creatine's Muscle Effects?

Alendronate inhibits osteoclast-mediated bone resorption. Creatine improves ATP regeneration during resistance exercise, which loads bone mechanically and activates osteoblasts through mechanotransduction. These effects operate on entirely different cell types and signaling cascades. No evidence suggests one blunts the other.

The framework below organizes what is known about this combination for clinical decision-making:

| Feature | Alendronate | Creatine Monohydrate | Combined | |---|---|---|---| | Mechanism | Osteoclast inhibition (FPP synthase) | ATP/phosphocreatine replenishment | Complementary, non-overlapping | | Renal elimination | Yes, unchanged | Creatinine via passive filtration | Both depend on CrCl monitoring | | Lab artifact risk | None | Creatinine up 10 to 20% | Requires baseline CMP | | Absorption interaction | Vulnerable to divalent cations | None with bisphosphonates | Separate by 30 min minimum | | Bone effect | Proven anti-resorptive | Indirect via exercise loading | Potentially additive | | Contraindication overlap | CrCl <35 mL/min | No absolute renal contraindication | Monitor CrCl if near threshold |

What Published Guidelines and Experts Say

FDA Labeling on Alendronate and Renal Function

The FDA prescribing information for alendronate sodium states: "Alendronate is not recommended for patients with creatinine clearance less than 35 mL/min" [1]. This restriction exists because the drug accumulates on bone surfaces and has not been studied in severe renal impairment. It does not mention supplements specifically, but the creatinine monitoring implication is direct.

Endocrine Society Position on Osteoporosis Medications

The 2022 Endocrine Society clinical practice guideline on pharmacological management of osteoporosis states that "bisphosphonates remain the first-line pharmacological treatment for most patients with osteoporosis" and specifies that renal function should be assessed before initiating therapy and periodically during treatment [7]. The guideline does not address creatine specifically, but its renal monitoring directive applies to any factor that could distort the creatinine reading, including supplement use.

Natural Medicines Database Classification

The Natural Medicines Comprehensive Database (accessed via Therapeutic Research Faculty) classifies the creatine-alendronate pairing as a "minor" interaction based solely on the shared renal monitoring requirement, not on any pharmacokinetic mechanism. It recommends informing the prescriber of creatine use rather than contraindicating the combination.

Practical Dosing and Timing Protocol

Morning Sequencing for Weekly Alendronate

The standard alendronate dose for postmenopausal osteoporosis is 70 mg once weekly. The morning-dose protocol is non-negotiable for any form. Here is a workable daily schedule for patients taking both:

1. Wake up. Immediately take alendronate 70 mg with 8 oz of plain still water.
2. Remain upright (sitting, standing, or walking) for 30 full minutes. No lying down.
3. After the 30-minute window, take creatine monohydrate 3 to 5 g dissolved in water or juice.
4. Eat breakfast any time after that.

On the six days of the week when alendronate is not taken, creatine can be taken with food at any time.

Creatine Dosing: Skip the Loading Phase If CKD Is Borderline

Loading protocols (20 g/day for five to seven days) saturate muscle stores faster, but they produce the largest creatinine artifact and put the most transient stress on renal filtration. For patients with eGFR between 35 to 60 mL/min (CKD stage 3a-3b), the HealthRX medical team recommends going directly to a maintenance dose of 3 to 5 g/day. Muscle saturation is achieved within three to four weeks at maintenance dosing, with meaningfully less creatinine fluctuation [3]. Patients with eGFR above 60 mL/min who want to use a loading phase should get a creatinine recheck at day 7 before assuming the lab results from that week are interpretable.

Which Creatine Product to Choose

Creatine monohydrate is the most studied form and has no absorption advantage over buffered, ethyl ester, or hydrochloride forms in head-to-head trials. Plain creatine monohydrate powder dissolved in water contains no calcium, magnesium, or other chelating agents, making it the safest choice to take after the alendronate window. Multi-ingredient pre-workout formulas often contain calcium carbonate, magnesium citrate, or dairy-based proteins that could theoretically reduce alendronate absorption if the timing window is not respected.

Who Should Be More Cautious

Patients Near the eGFR 35 Threshold

Anyone with an eGFR between 35 to 50 mL/min should have their creatinine rechecked two to four weeks after starting creatine. The prescriber needs to know whether a new reading reflects genuine GFR change or simply reflects the supplementation. Getting a cystatin C-based eGFR alongside standard creatinine at that visit removes the ambiguity entirely.

Older Adults With Sarcopenia

Interestingly, this is exactly the population where creatine might offer the most benefit. Sarcopenic older adults with osteoporosis face dual threats: low bone mass and low muscle mass. A meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle (2017, N=721 participants across 22 trials) found creatine supplementation combined with resistance training produced a weighted mean difference of 1.37 kg in lean mass compared with placebo [8]. For a patient already taking alendronate for fracture prevention, adding creatine-augmented resistance training represents a reasonable adjunct strategy, provided labs are monitored.

Patients on NSAIDs or ACE Inhibitors Concurrently

NSAIDs reduce renal prostaglandin synthesis and can genuinely lower GFR, independent of creatine. ACE inhibitors occasionally cause creatinine bumps of 10 to 15% at initiation via afferent arteriole dilation. If a patient is on alendronate, creatine, and an NSAID or ACE inhibitor simultaneously, the independent contributions to creatinine elevation may stack. This does not mean avoid all three. It means a repeat CMP at four to six weeks after any change to the regimen is justified.

Summarizing the Risk-Benefit Picture

Creatine is one of the most extensively studied sports supplements in existence. A 2017 review in the Journal of the International Society of Sports Nutrition found no evidence of kidney damage in healthy adults at doses up to 30 g/day for five years [9]. The concern with alendronate is not toxicity from the combination. The concern is a lab measurement being misread.

Three steps prevent every foreseeable problem:

• Obtain a baseline CMP and eGFR before starting creatine.
• Tell your alendronate prescriber you are taking creatine so they can interpret any creatinine change in context.
• Take alendronate at least 30 minutes before creatine (and before any other food, drink, or supplement) on dosing days.

Patients with eGFR comfortably above 60 mL/min and no other renal risk factors can start maintenance-dose creatine without significant concern. The goal is not to avoid creatine but to make sure the pharmacist, prescriber, and laboratory all share the same information.

A 2022 position statement from the International Society of Sports Nutrition concluded: "Creatine monohydrate supplementation in healthy individuals does not produce clinically meaningful changes in kidney or liver function" [9]. For patients on alendronate, the qualification "healthy individuals" is the phrase to pay attention to. Lab monitoring turns that reassurance into a verified fact for your specific clinical situation.